N-naphthoyl-β-naltrexamine (NNTA), a highly selective and potent activator of μ/κ-opioid heteromers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 12, 2011, Pages 5098-5103

  Yekkirala, Ajay S ^a,b   Lunzer, Mary M ^a   McCurdy, Christopher R ^a   Powers, Michael D ^a   Kalyuzhny, Alexander E ^b   Roerig, Sandra C ^c   Portoghese, Philip S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Pain

Indexed keywords

KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; N NAPHTHOYL BETA NALTREXAMINE; NALTREXAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CELL STRAIN HEK293; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; GUINEA PIG; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAIL FLICK TEST;

ANALGESICS; ANIMALS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

MUS;

EID: 79953191134     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016277108     Document Type: Article

References (42)

1. Cox BM, et al. Opioid receptors. International Union of Basic and Clinical Pharmacology database (IUPHAR-DB). http://www.iuphar-db.org/DATABASE/ FamilyMenuForward?familyId=50. Accessed on February 21, 2011.
2. Gutstein HB, Akil H (2006) Opioid analgesics. Goodman & Gilman's The Pharmacologic Basis of Therapeutics, eds Brunton LL, Lazo JS, Parker KL (McGraw-Hill, New York), 11th Ed, Chap 21.
3. Erez M, Takemori AE, Portoghese PS (1982) Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites. J Med Chem 25:847-849. (Pubitemid 12056967)
4. Portoghese PS, Ronsisvalle G, Larson D, Takemori AE (1986) Synthesis and opioid antagonist bivalent ligands with conformationally restricted spacers. J Med Chem 28:1650-1653. (Pubitemid 16018189)
5. Gershengorn MC, Osman R (2001) Minireview: Insights into G protein-coupled receptor function using molecular models. Endocrinology 142:2-10. (Pubitemid 32183658)
6. Jordan BA, Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700. (Pubitemid 29289066)
7. Gomes I, et al. (2000) Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci RC110/1-RC110/5.
8. Charles AC, et al. (2003) Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. Mol Pharmacol 63:89-95. (Pubitemid 36043812)
9. Wang D, Sun X, Bohn LM, Sadée W (2005) Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. Mol Pharmacol 67:2173-2184. (Pubitemid 41007796)
10. Wang HL, et al. (2005) Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J Neurochem 92:1285-1294.
11. Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA (2003) Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 64:1317-1324. (Pubitemid 37532221)
12. Zhang YQ, Limbird LE (2004) Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles. Biochem Soc Trans 32:856-860. (Pubitemid 39524397)
13. Rios C, Gomes I, Devi LA (2004) Interactions between delta opioid receptors and alpha-adrenoceptors. Clin Exp Pharmacol Physiol 31:833-836. (Pubitemid 39556863)
14. Pfeiffer M, et al. (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277:19762-19772. (Pubitemid 34967492)
15. Pfeiffer M, et al. (2003) Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem 278:51630-51637. (Pubitemid 38020408)
16. Mackie K (2005) Cannabinoid receptor homo- and heterodimerization. Life Sci 77:1667-1673.
17. Chen C, et al. (2004) Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:175-186. (Pubitemid 38068398)
18. Milligan G (2004) G protein-coupled receptor dimerization: Function and ligand pharmacology. Mol Pharmacol 66:1-7.
19. Rachid AJ, O'Dowd BF, George SR (2005) Diversity and complexity of signaling though peptidergic G protein-coupled receptors. Endocrinology 145:2645-2652.
20. Angers S, Salahpour A, Bouvier M (2002) Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 42:409-435. (Pubitemid 34160532)
21. Gomes I, et al. (2001) G protein coupled receptor dimerization: Implications in modulating receptor function. J Mol Med 79:226-242. (Pubitemid 32646378)
22. Salahpour A, et al. (2004) Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J Biol Chem 279:33390-33397. (Pubitemid 39062987)
23. Terrillon S, et al. (2003) Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 17:677-691. (Pubitemid 36403579)
24. Hasbi A, et al. (2007) Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: Coregulation by agonists. Biochemistry 46:12997-13009. (Pubitemid 350086219)
25. Zheng Y, et al. (2009) Induction of heterodimerization of mu opioid (MOP) and type B cholecystokinin (CCKB) receptors by bivalent ligands. J Med Chem 52:247-258.
26. Daniels DJ, et al. (2005) Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci USA 102:19208-19213. (Pubitemid 43049591)
27. Lenard NR, Daniels DJ, Portoghese PS, Roerig SC (2007) Absence of conditioned place preference or reinstatement with bivalent ligands containing opioid mu agonist and delta antagonist pharmacophores. Eur J Pharmacol 566:75-82. (Pubitemid 46782790)
28. Yekkirala AS, et al. (2007) NNTA is a highly selective activator of mu/kappa opioid receptor heterodimers. In 37th Annual meeting of the Society for Neuroscience, San Diego, CA.
29. Yekkirala AS, et al. (2008) NNTA is a highly selective activator of mu/kappa opioid receptor heterodimers that does not produce any tolerance or dependence. In Hot-Topics, International Narcotics Research Conference, Charleston, SC.
30. Li G, et al. (2009) Corrections to design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective antagonists. J Med Chem 52:1416-1427.
31. Waldhoer M, et al. (2005) A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci USA 102:9050-9055. (Pubitemid 40881076)
32. van Rijn RM, Whistler JL (2009) The δ(1) opioid receptor is a heterodimer that opposes the actions of the δ(2) receptor on alcohol intake. Biol Psychiatry 66:777-784.
33. Kostenis E (2001) Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol Sci 22:560-564.
34. Yekkirala AS, Kalyuznhy AE, Portoghese PS (2010) Standard opioid agonists activate heteromeric opioid receptors: Evidence for morphine and [d-Ala2-MePhe4-Glyol5] enkephalin as selective μ-δ agonists ACS Chem. Neurosci 1:146-154.
35. Portoghese PS, Larson DL, Sayre LM, Fries DS, Takemori AE (1980) A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem 23:233-234. (Pubitemid 10129958)
36. Portoghese PS, Lipkowski AW, Takemori AE (1987) Binaltorphimine and norbinaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 40:1287-1292. (Pubitemid 17035103)
37. Lenard NR, Roerig SC (2005) Development of antinociceptive tolerance and physical dependence following morphine i.c.v. infusion in mice. Eur J Pharmacol 527:71-76. (Pubitemid 41745153)
38. Lunzer MM, Portoghese PS (2007) Selectivity of delta- and kappa-opioid ligands depends on the route of central administration in mice. J Pharmacol Exp Ther 322:166-171. (Pubitemid 46956372)
39. Wessendorf MW, Dooyema J (2001) Coexistence of kappa- and delta-opioid receptors in rat spinal cord axons. Neurosci Lett 298:151-154. (Pubitemid 32126374)
40. Bhushan RG, Sharma SK, Xie Z, Daniels DJ, Portoghese PS (2004) A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J Med Chem 47:2969-2972. (Pubitemid 38702692)
41. Mullaney I (1999) G proteins and their identification. Signal Transduction: A Practical Approach, ed Milligan G (Oxford Univ Press, London), 2nd Ed, pp 100-101.
42. Roy S, Barke RA, Loh HH (1998) MU-opioid receptor-knockout mice: Role of muopioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res 61:190-194. (Pubitemid 28511362)